Exact Mass: 463.2936834

Exact Mass Matches: 463.2936834

Found 326 metabolites which its exact mass value is equals to given mass value 463.2936834, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Gentamicin C2

Gentamicin C2 Pentaacetate Salt

C20H41N5O7 (463.30058360000004)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic

   

Sagamicin

2-[4,6-Diamino-3-[3-amino-6-(methylaminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.3005836)


Micronomicin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52093-21-7 (retrieved 2024-10-09) (CAS RN: 52093-21-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

gentamicin C2a

gentamicin C2a

C20H41N5O7 (463.30058360000004)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins

   

Bilastine

2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-1,3-benzodiazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid

C28H37N3O3 (463.2834772)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Bilastine is a second-generation piperidine H1-antihistamine. Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria.

   

LysoPE(P-18:1(9Z)/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-[(1Z,9Z)-octadeca-1,9-dien-1-yloxy]propoxy]phosphinic acid

C23H46NO6P (463.30625860000004)


LysoPE(P-18:1(9Z)/0:0) is a phospho-ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin and choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

   

3-Hydroxyarachidonoylcarnitine

3-{[(5Z,8Z,11Z,14Z)-3-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-4-(trimethylammonio)butanoic acid

C27H45NO5 (463.32975600000003)


3-Hydroxyarachidonoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z,14Z)-hydroxyicosa-5,8,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyarachidonoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyarachidonoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,8S,9E,11Z,14Z)-8-Hydroxyicosa-5,9,11,14-tetraenoylcarnitine

3-[(8-hydroxyicosa-5,9,11,14-tetraenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


(5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,8Z,10E,12S,14Z)-12-Hydroxyicosa-5,8,10,14-tetraenoylcarnitine

3-[(12-hydroxyicosa-5,8,10,14-tetraenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E,7Z,11Z,14Z)-9-Hydroxyicosa-5,7,11,14-tetraenoylcarnitine

3-[(9-hydroxyicosa-5,7,11,14-tetraenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine

3-[(3-hydroxyicosa-5,8,11,14-tetraenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,11Z,14Z)-3-hydroxyicosa-5,8,11,14-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(10E)-11-(3,4-Dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine

3-{[11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoyl]oxy}-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


(10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an (10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10E)-11-(3,4-dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-{3,4-Dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine

3-({11-[3,4-dimethyl-5-(prop-1-en-1-yl)furan-2-yl]undecanoyl}oxy)-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-{3,4-dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-Oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine

3-({10-[3-(oct-2-en-1-yl)oxiran-2-yl]deca-5,8-dienoyl}oxy)-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z)-10-[(2S,3R)-3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Chenodeoxycholylalanine

2-(4-{5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)propanoic acid

C27H45NO5 (463.32975600000003)


Chenodeoxycholylalanine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylalanine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Alanine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylalanine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylalanine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Deoxycholylalanine

2-(4-{5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)propanoic acid

C27H45NO5 (463.32975600000003)


Deoxycholylalanine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylalanine consists of the bile acid deoxycholic acid conjugated to the amino acid Alanine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylalanine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylalanine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Azd-4547

N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-(3,5-dimethylpiperazin-1-yl)benzamide

C26H33N5O3 (463.2583268000001)


   

Bucromarone

2-{4-[3-(dibutylamino)propoxy]-3,5-dimethylbenzoyl}-4H-chromen-4-one

C29H37NO4 (463.27224420000005)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent

   

Gentamicin C2

2-[(4,6-diamino-3-{[3-amino-6-(1-aminoethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl)oxy]-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.30058360000004)


   

GLP-1 antagonist

BENZAMIDE, N-[[4,5-DIMETHYL-1-[(2-METHYLPHENYL)METHYL]-1H-IMIDAZOL-2-YL]METHYL]-2,4-DIMETHOXY-N-(3-METHYLBUTYL)-

C28H37N3O3 (463.2834772)


   

Micronomicin

2-{[4,6-diamino-3-({3-amino-6-[(methylamino)methyl]oxan-2-yl}oxy)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.30058360000004)


   

Peregrine

11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate

C26H41NO6 (463.29337260000005)


   

14-O-Acetyl-talatisamine

14-O-Acetyl-talatisamine

C26H41NO6 (463.29337260000005)


   

Paraherquamide B

14-Demethyl-14-deoxyparaherquamide

C27H33N3O4 (463.2470938000001)


   

Deoxaphomin

Deoxaphomin

C29H37NO4 (463.27224420000005)


   

Cytochalasin T

Cytochalasin T

C29H37NO4 (463.27224420000005)


   

Cytochalasin Z1

Cytochalasin Z1

C29H37NO4 (463.27224420000005)


   

Pingpeimine A

Pingpeimine A

C27H45NO5 (463.32975600000003)


   

UK 109692

30-Demethyl-14-deoxyparaherquamide

C27H33N3O4 (463.2470938000001)


   

Marcfortine B

Marcfortine B

C27H33N3O4 (463.2470938000001)


   

Phosphatidylethanolamine lyso alkenyl 18:1

Phosphatidylethanolamine lyso alkenyl 18:1

C23H46NO6P (463.30625860000004)


   

16beta-hydroxy-7.8-methylenedioxy-6-oxo-1alpha,14alpha,18-trimethoxy-N-ethylaconitane|6-oxocorumdephine

16beta-hydroxy-7.8-methylenedioxy-6-oxo-1alpha,14alpha,18-trimethoxy-N-ethylaconitane|6-oxocorumdephine

C25H37NO7 (463.2569892)


   

Mutamycin 1

Mutamycin 1

C19H37N5O8 (463.2642002)


   

4-Demethylgentamicin-C1

4-Demethylgentamicin-C1

C20H41N5O7 (463.30058360000004)


   

XK-62-3

XK-62-3

C20H41N5O7 (463.30058360000004)


   

5-epi-nakijiquinone S

5-epi-nakijiquinone S

C29H37NO4 (463.27224420000005)


   

chaetoconvosin A

chaetoconvosin A

C29H37NO4 (463.27224420000005)


   

(13E,21E)-(7S,16R)-6,7-epoxy-16-methyl-10-phenyl-[14]cytochalasa-13,21-diene-1,23-dione

(13E,21E)-(7S,16R)-6,7-epoxy-16-methyl-10-phenyl-[14]cytochalasa-13,21-diene-1,23-dione

C29H37NO4 (463.27224420000005)


   

(13E,21E)-(7S,16R,20R)-7,20-dihydroxy-16-methyl-10-phenyl-[14]-cytochalasa-5,13,21-triene-1,23-dione

(13E,21E)-(7S,16R,20R)-7,20-dihydroxy-16-methyl-10-phenyl-[14]-cytochalasa-5,13,21-triene-1,23-dione

C29H37NO4 (463.27224420000005)


   

C20H41N5O7

C20H41N5O7 (463.30058360000004)


   

SMTP-2

SMTP-2

C25H37NO7 (463.2569892)


   

Peregrine

Peregrine

C26H41NO6 (463.29337260000005)


   

guenerin

guenerin

C25H37NO7 (463.2569892)


   

anthriscifolcine G

anthriscifolcine G

C25H37NO7 (463.2569892)


   

Aconitan-6-one, 20-ethyl-10-hydroxy-1,14,16-trimethoxy-4-methyl-7,8-(methylenebis(oxy))-, (1alpha,14alpha,16beta)-

Aconitan-6-one, 20-ethyl-10-hydroxy-1,14,16-trimethoxy-4-methyl-7,8-(methylenebis(oxy))-, (1alpha,14alpha,16beta)-

C25H37NO7 (463.2569892)


   

anthriscifoldine A|delphidenine

anthriscifoldine A|delphidenine

C25H37NO7 (463.2569892)


   

N-neoselaginelloyl-L-phenylalanine

N-neoselaginelloyl-L-phenylalanine

C27H33N3O4 (463.2470938000001)


   

Peimisine HCl

(2R,3S,3R,3aS,4aS,6S,6aR,6bS,7aR,11aS,11bR)-1,2,3,3a,4,4,4a,5,6,6a,6b,7,7,7a,8,11,11a,11b-octadecahydro-3-hydroxy-3,6,10,11b-tetramethyl-spiro[9H-benzo[a]fluorene-9,2(3H)-furo[3,2-b]pyridin]-5(6H)-one, monohydrochloride

C27H42ClNO3 (463.28530520000004)


   

Alanine conjugated chenodeoxycholic acid

Alanine conjugated chenodeoxycholic acid

C27H45NO5 (463.32975600000003)


   

3-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid

"3-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid"

C27H45NO5 (463.32975600000003)


   

N-((4R)-4-((3R,5S,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

"N-((4R)-4-((3R,5S,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine"

C27H45NO5 (463.32975600000003)


   

N-((4R)-4-((3R,5S,7S,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

"N-((4R)-4-((3R,5S,7S,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine"

C27H45NO5 (463.32975600000003)


   

((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine

"((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine"

C26H41NO6 (463.29337260000005)


   

Ala Ala Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C21H33N7O5 (463.25430480000006)


   

Ala Ala Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C21H33N7O5 (463.25430480000006)


   

Ala Phe Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]propanamido]-5-carbamimidamidopentanoic acid

C21H33N7O5 (463.25430480000006)


   

Ala Phe Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]hexanamido]-3-methylbutanoic acid

C23H37N5O5 (463.27945520000003)


   

Ala Phe Arg Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]propanoic acid

C21H33N7O5 (463.25430480000006)


   

Ala Phe Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]-3-methylbutanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Ala Lys Phe Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C23H37N5O5 (463.27945520000003)


   

Ala Lys Val Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-methylbutanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Ala Arg Ala Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]propanamido]-3-phenylpropanoic acid

C21H33N7O5 (463.25430480000006)


   

Ala Arg Phe Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]propanoic acid

C21H33N7O5 (463.25430480000006)


   

Ala Val Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-3-phenylpropanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Ala Val Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]hexanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Cys Ile Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-methylpentanamido]hexanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Ile Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S,3S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-methylpentanamido]-3-hydroxybutanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Lys Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Lys Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Lys Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Lys Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Leu Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-methylpentanamido]hexanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Leu Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-methylpentanamido]-3-hydroxybutanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Thr Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-methylpentanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Thr Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]hexanamido]-3-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Thr Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]hexanamido]-4-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Cys Thr Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-4-methylpentanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Phe Ala Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]propanamido]-5-carbamimidamidopentanoic acid

C21H33N7O5 (463.25430480000006)


   

Phe Ala Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]hexanamido]-3-methylbutanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Ala Arg Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]-5-carbamimidamidopentanamido]propanoic acid

C21H33N7O5 (463.25430480000006)


   

Phe Ala Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]-3-methylbutanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Gly Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-3-methylpentanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Gly Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}hexanamido]-3-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Gly Lys Leu

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}hexanamido]-4-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Gly Leu Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-4-methylpentanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Ile Gly Lys

(2S)-6-amino-2-{2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]acetamido}hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Ile Lys Gly

2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]hexanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Phe Lys Ala Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]propanamido]-3-methylbutanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Lys Gly Ile

(2S,3S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]acetamido}-3-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Lys Gly Leu

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]acetamido}-4-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Lys Ile Gly

2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-methylpentanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Phe Lys Leu Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-4-methylpentanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Phe Lys Val Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-methylbutanamido]propanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Leu Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]acetamido}hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Leu Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]hexanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Phe Arg Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]propanamido]propanoic acid

C21H33N7O5 (463.25430480000006)


   

Phe Val Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]propanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Phe Val Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]hexanamido]propanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Phe Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-3-methylpentanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Phe Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]hexanamido]-3-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Phe Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]hexanamido]-4-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Phe Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-4-methylpentanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Ile Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-3-phenylpropanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Ile Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]hexanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Lys Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Lys Phe Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Lys Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Lys Leu Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Leu Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-3-phenylpropanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Gly Leu Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]hexanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Ile Cys Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-sulfanylpropanamido]hexanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Ile Cys Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Ile Phe Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]acetamido}hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Ile Phe Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]hexanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Ile Gly Phe Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}-3-phenylpropanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Ile Gly Lys Phe

(2S)-2-[(2S)-6-amino-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}hexanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Ile Lys Cys Thr

(2S,3R)-2-[(2R)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Ile Lys Phe Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-phenylpropanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Ile Lys Gly Phe

(2S)-2-{2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]acetamido}-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Ile Lys Thr Cys

(2R)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Ile Thr Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Ile Thr Lys Cys

(2R)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]hexanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Ala Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Ala Val Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-methylbutanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Cys Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Cys Leu Thr

(2S,3R)-2-[(2S)-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Cys Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Cys Thr Leu

(2S)-2-[(2S,3R)-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Phe Ala Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]propanamido]-3-methylbutanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Phe Gly Ile

(2S,3S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]acetamido}-3-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Phe Gly Leu

(2S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]acetamido}-4-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Phe Ile Gly

2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-3-methylpentanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Lys Phe Leu Gly

2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-4-methylpentanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Lys Phe Val Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]-3-methylbutanamido]propanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Gly Phe Ile

(2S,3S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-phenylpropanamido]-3-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Gly Phe Leu

(2S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-phenylpropanamido]-4-methylpentanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Gly Ile Phe

(2S)-2-[(2S,3S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylpentanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Gly Leu Phe

(2S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-4-methylpentanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Ile Cys Thr

(2S,3R)-2-[(2R)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Ile Phe Gly

2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-phenylpropanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Lys Ile Gly Phe

(2S)-2-{2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]acetamido}-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Ile Thr Cys

(2R)-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Leu Cys Thr

(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Leu Phe Gly

2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-phenylpropanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Lys Leu Gly Phe

(2S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]acetamido}-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Leu Thr Cys

(2R)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Met Ser Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]-3-methylbutanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Met Val Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanamido]-3-hydroxypropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Ser Met Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Ser Val Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Thr Cys Ile

(2S,3S)-2-[(2R)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Thr Cys Leu

(2S)-2-[(2R)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-4-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Thr Ile Cys

(2R)-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-methylpentanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Thr Leu Cys

(2R)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-4-methylpentanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Val Ala Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]propanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Val Phe Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-phenylpropanamido]propanoic acid

C23H37N5O5 (463.27945520000003)


   

Lys Val Met Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanoic acid

C19H37N5O6S (463.24644220000005)


   

Lys Val Ser Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanoic acid

C19H37N5O6S (463.24644220000005)


   

Leu Cys Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2R)-2-[(2S)-2-amino-4-methylpentanamido]-3-sulfanylpropanamido]hexanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Leu Cys Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2R)-2-[(2S)-2-amino-4-methylpentanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Leu Phe Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]acetamido}hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Leu Phe Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]hexanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Leu Gly Phe Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}-3-phenylpropanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Leu Gly Lys Phe

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}hexanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Leu Lys Cys Thr

(2S,3R)-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C19H37N5O6S (463.24644220000005)


   

Leu Lys Phe Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-phenylpropanamido]acetic acid

C23H37N5O5 (463.27945520000003)


   

Leu Lys Gly Phe

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]acetamido}-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Leu Lys Thr Cys

(2R)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Leu Thr Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Leu Thr Lys Cys

(2R)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]hexanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Met Lys Ser Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]hexanamido]-3-hydroxypropanamido]-3-methylbutanoic acid

C19H37N5O6S (463.24644220000005)


   

Met Lys Val Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]hexanamido]-3-methylbutanamido]-3-hydroxypropanoic acid

C19H37N5O6S (463.24644220000005)


   

Met Ser Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]hexanamido]-3-methylbutanoic acid

C19H37N5O6S (463.24644220000005)


   

Met Ser Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]-3-methylbutanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Met Val Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-methylbutanamido]hexanamido]-3-hydroxypropanoic acid

C19H37N5O6S (463.24644220000005)


   

Met Val Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-methylbutanamido]-3-hydroxypropanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Arg Ala Ala Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]propanamido]-3-phenylpropanoic acid

C21H33N7O5 (463.25430480000006)


   

Arg Ala Phe Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]-3-phenylpropanamido]propanoic acid

C21H33N7O5 (463.25430480000006)


   

Arg Phe Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]propanamido]propanoic acid

C21H33N7O5 (463.25430480000006)


   

Ser Lys Met Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanoic acid

C19H37N5O6S (463.24644220000005)


   

Ser Lys Val Met

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanoic acid

C19H37N5O6S (463.24644220000005)


   

Ser Met Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]hexanamido]-3-methylbutanoic acid

C19H37N5O6S (463.24644220000005)


   

Ser Met Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Ser Val Lys Met

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]hexanamido]-4-(methylsulfanyl)butanoic acid

C19H37N5O6S (463.24644220000005)


   

Ser Val Met Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Cys Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-methylpentanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Cys Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]hexanamido]-3-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Cys Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]hexanamido]-4-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Cys Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-4-methylpentanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Ile Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]-3-sulfanylpropanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Ile Lys Cys

(2R)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]hexanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Lys Cys Ile

(2S,3S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-sulfanylpropanamido]-3-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Lys Cys Leu

(2S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-sulfanylpropanamido]-4-methylpentanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Lys Ile Cys

(2R)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-methylpentanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Lys Leu Cys

(2R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-4-methylpentanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Leu Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]-3-sulfanylpropanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Thr Leu Lys Cys

(2R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]hexanamido]-3-sulfanylpropanoic acid

C19H37N5O6S (463.24644220000005)


   

Val Ala Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]-3-phenylpropanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Val Ala Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]hexanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Val Phe Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]propanamido]hexanoic acid

C23H37N5O5 (463.27945520000003)


   

Val Phe Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]hexanamido]propanoic acid

C23H37N5O5 (463.27945520000003)


   

Val Lys Ala Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]propanamido]-3-phenylpropanoic acid

C23H37N5O5 (463.27945520000003)


   

Val Lys Phe Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-phenylpropanamido]propanoic acid

C23H37N5O5 (463.27945520000003)


   

Val Lys Met Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanoic acid

C19H37N5O6S (463.24644220000005)


   

Val Lys Ser Met

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanoic acid

C19H37N5O6S (463.24644220000005)


   

Val Met Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-(methylsulfanyl)butanamido]hexanamido]-3-hydroxypropanoic acid

C19H37N5O6S (463.24644220000005)


   

Val Met Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

Val Ser Lys Met

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxypropanamido]hexanamido]-4-(methylsulfanyl)butanoic acid

C19H37N5O6S (463.24644220000005)


   

Val Ser Met Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]hexanoic acid

C19H37N5O6S (463.24644220000005)


   

PA(19:3/0:0)

1-(10Z,13Z,16Z-nonadecatrienoyl)-sn-glycero-3-phosphate (Ammonium salt)

C22H42NO7P (463.26987520000006)


   

PE(17:2(9Z,12Z)/0:0)

1-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphoethanolamine

C22H42NO7P (463.26987520000006)


   

CAR 20:4;O

3-{[(5Z,8Z,11Z,14Z)-3-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-4-(trimethylazaniumyl)butanoate

C27H45NO5 (463.32975600000003)


   

LPE 17:2

1-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphoethanolamine

C22H42NO7P (463.26987520000006)


   

Azd-4547

Azd-4547

C26H33N5O3 (463.2583268000001)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor

   

AQ-RA 741

11-[[4-[4-(Diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-B][1,4]benzodiazepin-6-one

C27H37N5O2 (463.2947102)


   

tert-butyl 2-[2-[(2-amino-2-cyclohexylacetyl)amino]-3,3-dimethylbutanoyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxylate

tert-butyl 2-[2-[(2-amino-2-cyclohexylacetyl)amino]-3,3-dimethylbutanoyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxylate

C26H45N3O4 (463.34098900000004)


   

(3β,5α,6α,16β)-Cevane-3,6,14,16,20-pentol

(3β,5α,6α,16β)-Cevane-3,6,14,16,20-pentol

C27H45NO5 (463.32975600000003)


   

UNC 2881

UNC 2881

C25H33N7O2 (463.2695598)


   

Valsartan Ethyl Ester

Valsartan Ethyl Ester

C26H33N5O3 (463.2583268000001)


Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure[1].

   

Sarcoursodeoxycholic acid

Sarcoursodeoxycholic acid

C27H45NO5 (463.32975600000003)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   

bilastine

bilastine

C28H37N3O3 (463.2834772)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria.

   

Bucromarone

Bucromarone

C29H37NO4 (463.27224420000005)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent

   

3,7,12-Trihydroxycoprostanate

3,7,12-Trihydroxycoprostanate

C28H47O5- (463.3423312)


   

LysoPE(P-18:1(9Z)/0:0)

LysoPE(P-18:1(9Z)/0:0)

C23H46NO6P (463.30625860000004)


   

Deoxycholylalanine

Deoxycholylalanine

C27H45NO5 (463.32975600000003)


   

(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine

(5Z,8Z,11Z,14Z)-3-Icosa-5,8,11,14-tetraenoylcarnitine

C27H45NO5 (463.32975600000003)


   

(5E,7Z,11Z,14Z)-9-Hydroxyicosa-5,7,11,14-tetraenoylcarnitine

(5E,7Z,11Z,14Z)-9-Hydroxyicosa-5,7,11,14-tetraenoylcarnitine

C27H45NO5 (463.32975600000003)


   

(5Z,8S,9E,11Z,14Z)-8-Hydroxyicosa-5,9,11,14-tetraenoylcarnitine

(5Z,8S,9E,11Z,14Z)-8-Hydroxyicosa-5,9,11,14-tetraenoylcarnitine

C27H45NO5 (463.32975600000003)


   

(5Z,8Z,10E,12S,14Z)-12-Hydroxyicosa-5,8,10,14-tetraenoylcarnitine

(5Z,8Z,10E,12S,14Z)-12-Hydroxyicosa-5,8,10,14-tetraenoylcarnitine

C27H45NO5 (463.32975600000003)


   

(10E)-11-(3,4-Dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine

(10E)-11-(3,4-Dimethyl-5-propylfuran-2-yl)undec-10-enoylcarnitine

C27H45NO5 (463.32975600000003)


   

11-{3,4-Dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine

11-{3,4-Dimethyl-5-[(1E)-prop-1-en-1-yl]furan-2-yl}undecanoylcarnitine

C27H45NO5 (463.32975600000003)


   

(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-Oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine

(5Z,8Z)-10-[(2S,3R)-3-[(2Z)-Oct-2-en-1-yl]oxiran-2-yl]deca-5,8-dienoylcarnitine

C27H45NO5 (463.32975600000003)


   

2-(2,4-dimethoxyanilino)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-quinolinecarboxamide

2-(2,4-dimethoxyanilino)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-quinolinecarboxamide

C26H33N5O3 (463.2583268000001)


   

3-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-6-ethyl-1H-quinolin-2-one

3-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-6-ethyl-1H-quinolin-2-one

C25H33N7O2 (463.2695598)


   

3-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-5,7-dimethyl-1H-quinolin-2-one

3-[3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-5,7-dimethyl-1H-quinolin-2-one

C25H33N7O2 (463.2695598)


   

N-((4R)-4-((3R,5S,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

N-((4R)-4-((3R,5S,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

C27H45NO5 (463.32975600000003)


   

(1R,2S,3R,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-alpha-D-ribo-heptopyranoside

(1R,2S,3R,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-alpha-D-ribo-heptopyranoside

C20H41N5O7 (463.30058360000004)


   

N-[(3alpha,5beta,12alpha)-3,12-dihydroxy-7,24-dioxocholan-24-yl]glycine

N-[(3alpha,5beta,12alpha)-3,12-dihydroxy-7,24-dioxocholan-24-yl]glycine

C26H41NO6 (463.29337260000005)


   

(2S,3R)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3R)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H37N3O3 (463.2834772)


   

1-[(1S)-1-(hydroxymethyl)-7-methoxy-1-(phenylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone

1-[(1S)-1-(hydroxymethyl)-7-methoxy-1-(phenylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone

C27H33N3O4 (463.2470938000001)


   

N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

(2R,3S)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-8-(1-cyclohexenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H37N3O3 (463.2834772)


   

(2R,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H37N3O3 (463.2834772)


   

(1R,9S,10S,11S)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-N,N-dimethyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1R,9S,10S,11S)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-N,N-dimethyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C27H33N3O4 (463.2470938000001)


   

(8S,9S,10S)-9-[4-(1-cyclohexenyl)phenyl]-N-(2-fluorophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide

(8S,9S,10S)-9-[4-(1-cyclohexenyl)phenyl]-N-(2-fluorophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide

C28H34FN3O2 (463.2634916)


   

(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-1-(3-pyridinylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide

(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-1-(3-pyridinylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide

C26H33N5O3 (463.2583268000001)


   

(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propan-2-yl-2-(2-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide

(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propan-2-yl-2-(2-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide

C26H33N5O3 (463.2583268000001)


   

N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C27H33N3O4 (463.2470938000001)


   

(2R)-2-[(4S,5R)-5-[[cyclopropylmethyl(methyl)amino]methyl]-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4S,5R)-5-[[cyclopropylmethyl(methyl)amino]methyl]-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C24H37N3O4S (463.25046420000007)


   

(2S,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H37N3O3 (463.2834772)


   

(2S,3R)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3R)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C28H37N3O3 (463.2834772)


   

(1S,9R,10R,11R)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-N,N-dimethyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1S,9R,10R,11R)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-N,N-dimethyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C27H33N3O4 (463.2470938000001)


   

(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C27H33N3O4 (463.2470938000001)


   

(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C27H33N3O4 (463.2470938000001)


   

(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-1-(3-pyridinylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide

(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-1-(3-pyridinylmethyl)-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide

C26H33N5O3 (463.2583268000001)


   

[(1S)-1-(cyclopropylmethyl)-2-[(2-fluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

[(1S)-1-(cyclopropylmethyl)-2-[(2-fluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C28H34FN3O2 (463.2634916)


   

1-[(1R)-1-(hydroxymethyl)-7-methoxy-1-(phenylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone

1-[(1R)-1-(hydroxymethyl)-7-methoxy-1-(phenylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-2-methoxyethanone

C27H33N3O4 (463.2470938000001)


   

3-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid

3-((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid

C27H45NO5 (463.32975600000003)


   

((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine

((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine

C26H41NO6 (463.29337260000005)


   

(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C27H33N3O4 (463.2470938000001)


   

(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-[(2-methoxyphenyl)methyl]-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C27H33N3O4 (463.2470938000001)


   

HexCer 8:0;2O/9:0

HexCer 8:0;2O/9:0

C23H45NO8 (463.314501)


   

HexCer 9:0;2O/8:0

HexCer 9:0;2O/8:0

C23H45NO8 (463.314501)


   

HexCer 11:0;2O/6:0

HexCer 11:0;2O/6:0

C23H45NO8 (463.314501)


   

HexCer 14:0;2O/3:0

HexCer 14:0;2O/3:0

C23H45NO8 (463.314501)


   

HexCer 13:0;2O/4:0

HexCer 13:0;2O/4:0

C23H45NO8 (463.314501)


   

HexCer 15:0;2O/2:0

HexCer 15:0;2O/2:0

C23H45NO8 (463.314501)


   

HexCer 10:0;2O/7:0

HexCer 10:0;2O/7:0

C23H45NO8 (463.314501)


   

HexCer 12:0;2O/5:0

HexCer 12:0;2O/5:0

C23H45NO8 (463.314501)


   

2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] hydrogen phosphate

2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] hydrogen phosphate

C23H46NO6P (463.30625860000004)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate

C22H42NO7P (463.26987520000006)


   

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dec-4-ene-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]undecane-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]decane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]decane-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)undec-4-ene-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

2-(Decanoylamino)-3-hydroxytetradecane-1-sulfonic acid

2-(Decanoylamino)-3-hydroxytetradecane-1-sulfonic acid

C24H49NO5S (463.3331264000001)


   

3-Hydroxy-2-(tridecanoylamino)undecane-1-sulfonic acid

3-Hydroxy-2-(tridecanoylamino)undecane-1-sulfonic acid

C24H49NO5S (463.3331264000001)


   

2-(Dodecanoylamino)-3-hydroxydodecane-1-sulfonic acid

2-(Dodecanoylamino)-3-hydroxydodecane-1-sulfonic acid

C24H49NO5S (463.3331264000001)


   

3-Hydroxy-2-(tetradecanoylamino)decane-1-sulfonic acid

3-Hydroxy-2-(tetradecanoylamino)decane-1-sulfonic acid

C24H49NO5S (463.3331264000001)


   

3-Hydroxy-2-(undecanoylamino)tridecane-1-sulfonic acid

3-Hydroxy-2-(undecanoylamino)tridecane-1-sulfonic acid

C24H49NO5S (463.3331264000001)


   

cis-5-(6-Carboxyhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

cis-5-(6-Carboxyhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

C30H41NO3 (463.3086276)


   

(3S)-5beta-(6-Formylhexyl)-4alpha-[(E)-3-hydroxy-1-octenyl]-2,3alpha-diphenylisoxazolidine

(3S)-5beta-(6-Formylhexyl)-4alpha-[(E)-3-hydroxy-1-octenyl]-2,3alpha-diphenylisoxazolidine

C30H41NO3 (463.3086276)


   

lysoDGTS 16:5

lysoDGTS 16:5

C26H41NO6 (463.29337260000005)


   

lysoPE 17:2

lysoPE 17:2

C22H42NO7P (463.26987520000006)


   

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

2-[[(4E,8E)-2-acetamido-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-acetamido-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

Micronomicin

(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(methylaminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.3005836)


Micronomicin is an antibiotic that belongs to the aminoglycoside class of organic compounds. Aminoglycosides are characterized by aminocyclitols linked to amino sugars, forming aminoglycoside antibiotics. These compounds are known for their broad-spectrum activity against various microorganisms, particularly bacteria. Micronomicin, specifically, features a structure where an aminocyclitol is connected to an amino sugar through a glycosidic bond. This structure is typical of aminoglycosides and contributes to their antimicrobial properties. The exact configuration and arrangement of atoms in micronomicin give it its specific antimicrobial profile. Micronomicin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52093-21-7 (retrieved 2024-10-09) (CAS RN: 52093-21-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

3-hydroxyarachidonoylcarnitine

3-hydroxyarachidonoylcarnitine

C27H45NO5 (463.32975600000003)


An O-acylcarnitine having 3-hydroxyarachidonoyl as the acyl substituent.

   

1-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphoethanolamine

1-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphoethanolamine

C22H42NO7P (463.26987520000006)


   

lysophosphatidylcholine 14:2

lysophosphatidylcholine 14:2

C22H42NO7P (463.26987520000006)


A lysophosphatidylcholine in which the remaining acyl group contains 14 carbons and 2 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.

   

lysophosphatidylethanolamine P-18:1

lysophosphatidylethanolamine P-18:1

C23H46NO6P (463.30625860000004)


A 1-(Z-alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the Z-alk-1-enyl group contains 18 carbons and has 1 additional double bond

   

gentamycin C2

gentamycin C2

C20H41N5O7 (463.30058360000004)


   

NA-Cit 20:3(8Z,11Z,14Z)

NA-Cit 20:3(8Z,11Z,14Z)

C26H45N3O4 (463.34098900000004)


   

NA-DOPA 18:0

NA-DOPA 18:0

C27H45NO5 (463.32975600000003)


   

NA-Dopamine 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Dopamine 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

C30H41NO3 (463.3086276)


   

NA-Met 22:4(7Z,10Z,13Z,16Z)

NA-Met 22:4(7Z,10Z,13Z,16Z)

C27H45NO3S (463.311998)


   

CAR 20:4;OH

CAR 20:4;OH

C27H45NO5 (463.32975600000003)


   

LPC 14:2

LPC 14:2

C22H42NO7P (463.26987520000006)


   

LysoPE O-18:2

LPE O-18:2

C23H46NO6P (463.30625860000004)


   

LPE P-18:1

LPE P-18:1

C23H46NO6P (463.30625860000004)


   

LPE P-18:1 or LPE O-18:2

LPE P-18:1 or LPE O-18:2

C23H46NO6P (463.30625860000004)


   

Ala-CDCA

Ala-CDCA

C27H45NO5 (463.32975600000003)


   

Ala-DCA

Ala-DCA

C27H45NO5 (463.32975600000003)


   

Ala-HDCA

Ala-HDCA

C27H45NO5 (463.32975600000003)


   

Ala-UDCA

Ala-UDCA

C27H45NO5 (463.32975600000003)


   

ST 23:3;O5;Gly

ST 23:3;O5;Gly

C25H37NO7 (463.2569892)


   

ST 24:2;O4;Gly

ST 24:2;O4;Gly

C26H41NO6 (463.29337260000005)


   

ST 25:1;O3;Gly

ST 25:1;O3;Gly

C27H45NO5 (463.32975600000003)


   

ST 27:7;O2;Gly

ST 27:7;O2;Gly

C29H37NO4 (463.27224420000005)


   

ST 18:1;O;HexNAc

ST 18:1;O;HexNAc

C26H41NO6 (463.29337260000005)


   

NMI 8739

NMI 8739

C30H41NO3 (463.3086276)


NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

   

(1s,12r,14r,15r,16s,17s,20s)-14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

(1s,12r,14r,15r,16s,17s,20s)-14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

C30H41NO3 (463.3086276)


   

16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

C29H37NO4 (463.27224420000005)


   

(1'r,3's,7's,8r,12's)-4,4,4',4',12'-pentamethyl-9',14'-diazaspiro[[1,4]dioxepino[2,3-g]indole-8,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-9,13'-diol

(1'r,3's,7's,8r,12's)-4,4,4',4',12'-pentamethyl-9',14'-diazaspiro[[1,4]dioxepino[2,3-g]indole-8,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecan]-13'-ene-9,13'-diol

C27H33N3O4 (463.2470938000001)


   

(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate

(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate

C26H41NO6 (463.29337260000005)


   

(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-14-en-4-yl acetate

(1s,2r,3r,4s,5r,6s,8r,9s,10s,13r,16s,17r,18s)-11-ethyl-9,16,18-trihydroxy-6,8-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-14-en-4-yl acetate

C25H37NO7 (463.2569892)


   

(3s,3ar,4s,6s,6as,10r,14s,17ar)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one

(3s,3ar,4s,6s,6as,10r,14s,17ar)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindol-17-one

C29H37NO4 (463.27224420000005)


   

(5r,9r,12ar,15s,15as,16s,18as)-16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

(5r,9r,12ar,15s,15as,16s,18as)-16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

C29H37NO4 (463.27224420000005)


   

(5r,9r,12as,15s,15as,16s,18ar)-16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

(5r,9r,12as,15s,15as,16s,18ar)-16-benzyl-5,18-dihydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

C29H37NO4 (463.27224420000005)